761 related articles for article (PubMed ID: 23701942)
21. Prognostic impact of stromal and intratumoral CD3, CD8 and FOXP3 in adjuvantly treated breast cancer: do they add information over stromal tumor-infiltrating lymphocyte density?
Koletsa T; Kotoula V; Koliou GA; Manousou K; Chrisafi S; Zagouri F; Sotiropoulou M; Pentheroudakis G; Papoudou-Bai A; Christodoulou C; Xepapadakis G; Zografos G; Petraki K; Pazarli E; Koutras A; Kourea HP; Bafaloukos D; Chatzopoulos K; Iliadis A; Markopoulos C; Venizelos V; Arnogiannaki N; Kalogeras KT; Kostopoulos I; Gogas H; Fountzilas G
Cancer Immunol Immunother; 2020 Aug; 69(8):1549-1564. PubMed ID: 32303794
[TBL] [Abstract][Full Text] [Related]
22. Changes of tumor infiltrating lymphocyte subtypes before and after neoadjuvant endocrine therapy in estrogen receptor-positive breast cancer patients--an immunohistochemical study of Cd8+ and Foxp3+ using double immunostaining with correlation to the pathobiological response of the patients.
Chan MS; Wang L; Felizola SJ; Ueno T; Toi M; Loo W; Chow LW; Suzuki T; Sasano H
Int J Biol Markers; 2012 Dec; 27(4):e295-304. PubMed ID: 23280127
[TBL] [Abstract][Full Text] [Related]
23. Predictive and prognostic role of tumour-infiltrating lymphocytes in breast cancer patients with different molecular subtypes: a meta-analysis.
Gao ZH; Li CX; Liu M; Jiang JY
BMC Cancer; 2020 Nov; 20(1):1150. PubMed ID: 33238978
[TBL] [Abstract][Full Text] [Related]
24. Tumor-associated lymphocytes and macrophages are related to stromal elastosis and vascular invasion in breast cancer.
Chen Y; Klingen TA; Aas H; Wik E; Akslen LA
J Pathol Clin Res; 2021 Sep; 7(5):517-527. PubMed ID: 34076969
[TBL] [Abstract][Full Text] [Related]
25. Androgen receptor expression is usually maintained in initial surgically resected breast cancer metastases but is often lost in end-stage metastases found at autopsy.
Cimino-Mathews A; Hicks JL; Illei PB; Halushka MK; Fetting JH; De Marzo AM; Park BH; Argani P
Hum Pathol; 2012 Jul; 43(7):1003-11. PubMed ID: 22154362
[TBL] [Abstract][Full Text] [Related]
26. The predictive and prognostic value of Foxp3+/CD25+ regulatory T cells and PD-L1 expression in triple negative breast cancer.
Zhang L; Wang XI; Ding J; Sun Q; Zhang S
Ann Diagn Pathol; 2019 Jun; 40():143-151. PubMed ID: 31096176
[TBL] [Abstract][Full Text] [Related]
27. Prognostic significance of infiltrating immune cell subtypes in invasive ductal carcinoma of the breast.
Xu Y; Lan S; Zheng Q
Tumori; 2018 Jun; 104(3):196-201. PubMed ID: 28430349
[TBL] [Abstract][Full Text] [Related]
28. Levels of different subtypes of tumour-infiltrating lymphocytes correlate with each other, with matched circulating lymphocytes, and with survival in breast cancer.
Verma R; Hanby AM; Horgan K; Verghese ET; Volpato M; Carter CR; Hughes TA
Breast Cancer Res Treat; 2020 Aug; 183(1):49-59. PubMed ID: 32577938
[TBL] [Abstract][Full Text] [Related]
29. Cancer-immune interactions in ER-positive breast cancers: PI3K pathway alterations and tumor-infiltrating lymphocytes.
Sobral-Leite M; Salomon I; Opdam M; Kruger DT; Beelen KJ; van der Noort V; van Vlierberghe RLP; Blok EJ; Giardiello D; Sanders J; Van de Vijver K; Horlings HM; Kuppen PJK; Linn SC; Schmidt MK; Kok M
Breast Cancer Res; 2019 Aug; 21(1):90. PubMed ID: 31391067
[TBL] [Abstract][Full Text] [Related]
30. Comparison of ER, PR and HER-2/neu (C-erb B 2) reactivity pattern with histologic grade, tumor size and lymph node status in breast cancer.
Azizun-Nisa ; Bhurgri Y; Raza F; Kayani N
Asian Pac J Cancer Prev; 2008; 9(4):553-6. PubMed ID: 19256737
[TBL] [Abstract][Full Text] [Related]
31. Prognostic impact of a tumor-infiltrating lymphocyte subtype in triple negative cancer of the breast.
Jamiyan T; Kuroda H; Yamaguchi R; Nakazato Y; Noda S; Onozaki M; Abe A; Hayashi M
Breast Cancer; 2020 Sep; 27(5):880-892. PubMed ID: 32222891
[TBL] [Abstract][Full Text] [Related]
32. Importance of CD45RO+ tumor-infiltrating lymphocytes in post-operative survival of breast cancer patients.
Ahmadvand S; Faghih Z; Montazer M; Safaei A; Mokhtari M; Jafari P; Talei AR; Tahmasebi S; Ghaderi A
Cell Oncol (Dordr); 2019 Jun; 42(3):343-356. PubMed ID: 30825183
[TBL] [Abstract][Full Text] [Related]
33. PD-L1 and CD8 are associated with deficient mismatch repair status in triple-negative and HER2-positive breast cancers.
Hou Y; Nitta H; Parwani AV; Li Z
Hum Pathol; 2019 Apr; 86():108-114. PubMed ID: 30633926
[TBL] [Abstract][Full Text] [Related]
34. Clinicopathologic Features and Immune Cell Subtypes Analysis of Tumor-infiltrating Lymphocytes Rich Invasive Breast Carcinoma of No Special Type.
Zhao Y; Huang T; Jin X; Gong XM; Lu YZ
Appl Immunohistochem Mol Morphol; 2023 Jul; 31(6):354-362. PubMed ID: 37278279
[TBL] [Abstract][Full Text] [Related]
35. Levels of lymphocyte subsets in peripheral blood prior treatment are associated with aggressive breast cancer phenotypes or subtypes.
Jia Y; Xu L; Lin Q; Zhu M; Ding L; Wu K; Lu Y
Med Oncol; 2014 Jun; 31(6):981. PubMed ID: 24798876
[TBL] [Abstract][Full Text] [Related]
36. Prognostic Value of Tumor Infiltrating Lymphocytes in Locally Advanced HER2 Enriched Breast Cancer.
Saber MM; El Zawahry HM; Hilal AM; Abou-Bakr AA; Namour AE; Saber MM
Asian Pac J Cancer Prev; 2022 Feb; 23(2):553-560. PubMed ID: 35225468
[TBL] [Abstract][Full Text] [Related]
37. An increase in tumor-infiltrating lymphocytes after treatment is significantly associated with a poor response to neoadjuvant endocrine therapy for estrogen receptor-positive/HER2-negative breast cancers.
Fukui R; Watanabe T; Morimoto K; Fujimoto Y; Nagahashi M; Ishikawa E; Hirota S; Miyoshi Y
Breast Cancer; 2023 Sep; 30(5):703-713. PubMed ID: 37115435
[TBL] [Abstract][Full Text] [Related]
38. Tumour-infiltrating lymphocytes and response to neoadjuvant letrozole in patients with early oestrogen receptor-positive breast cancer: analysis from a nationwide phase II DBCG trial.
Skriver SK; Jensen MB; Knoop AS; Ejlertsen B; Laenkholm AV
Breast Cancer Res; 2020 May; 22(1):46. PubMed ID: 32410705
[TBL] [Abstract][Full Text] [Related]
39. Unfavorable prognostic role of tumor-infiltrating lymphocytes in hormone-receptor positive, HER2 negative metastatic breast cancer treated with metronomic chemotherapy.
Montagna E; Vingiani A; Maisonneuve P; Cancello G; Contaldo F; Pruneri G; Colleoni M
Breast; 2017 Aug; 34():83-88. PubMed ID: 28544923
[TBL] [Abstract][Full Text] [Related]
40. A high CD8 to FOXP3 ratio in the tumor stroma and expression of PTEN in tumor cells are associated with improved survival in non-metastatic triple-negative breast carcinoma.
Tavares MC; Sampaio CD; Lima GE; Andrade VP; Gonçalves DG; Macedo MP; Cordeiro de Lima VC
BMC Cancer; 2021 Aug; 21(1):901. PubMed ID: 34362334
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
